In many different liver diseases, such as cirrhosis, degradation of the microcirculation, including obliteration of small portal or hepatic veins contributes to disease-associated portal hypertension. The present study demonstrates the importance of angiogenesis in the establishment of arteriovenous shunts and the accompanying changes to the venous bed. One aspect of angiogenesis involves the branching of new vessels from pre-existing ones, and the molecular mechanisms controlling it are complex and involve a coordinated effort between specific endothelial growth factors and their receptors, including the angiopoietins. We modulated the hepatic vasculature in mice by conditionally expressing angiopoietin-1 in hepatocytes. In mice exposed to angiopoietin-1 during development, arterial sprouting, enlarged arteries, marked loss of portal vein radicles, hepatic vein dilation, and suggestion of arteriovenous shunting were observed. Most importantly, these phenotypic changes were completely reversed within 14 days of turning off transgene expression. Expression of excess angiopoietin-1 beginning in adulthood did not fully recapitulate the phenotype, but did result in enlarged vessels. Our findings suggest that controlling excessive angiogenesis during liver disease may promote the restoration of the portal vein circuit and aid in the resolution of disease-associated portal hypertension. 
Many types of liver disease, including Budd-Chiari syndrome (BCS), hepatitis, cirrhosis, and focal nodular hyperplasia (FNH) are characterized by portal hypertension and liver failure. Histologically, they often involve fibrosis, nodular regeneration, and disturbed vascular architecture and it is these changes that account for the significant disturbance in the hepatic circulation. [1] [2] [3] [4] [5] [6] Historically these diseases have been widely regarded as irreversible, however several reports examining experimental animal models of fibrosis and human liver biopsies suggest that the fibrosis events related to some types of liver disease can be reversed. [7] [8] [9] Nonetheless, the portal hypertension associated with liver disease appears irreversible, and most likely reflects the presence of arteriovenous (AV) shunts and aberrant veins.
2,4 -6 These uncontrolled angiogenic events suggest that controlling blood vessel development and plasticity may provide important insight into alternative treatment strategies targeting the vasculature, in addition to current strategies targeting the hepatocytes.
Angiogenesis refers to the expansion or remodeling of pre-existing blood vessels and is critical during normal embryonic vascular development and in the progression of several diseases. 10 The molecular events governing angiogenesis are complex and involve multiple families of proteins and receptors, including the vascular endothelial growth factor family 11 and the angiopoietin (Ang) family. 10 Vascular endothelial growth factor is a potent angiogenic factor and in the liver, can contribute to the proliferation of sinusoidal endothelial cells (ECs) during liver regeneration 12, 13 and is increased after experimental induction of hepatic fibrosis and cirrhosis 14, 15 and in livers of patients suffering from cirrhosis, 15, 16 nodular regenerative hyperplasia (NRH), BCS, FNH, and other benign liver tumors. 4, 6, 17 Ang-1, a member of the Ang family, has also been shown to play a role in vascular development and vascular-related disease processes. 10 Ang-1 is the best characterized member of the Ang family and binds to Tie2, a receptor tyrosine kinase that is expressed on ECs lining blood vessels. 18, 19 In the vascular system, Ang-1 is involved in EC survival and migration, periendothelial cell recruitment, and tubule formation. 10 In the liver, increased expression of Ang-1, Ang-2, and their receptor Tie2 have been observed in regenerating liver, after hepatectomy, 20 -22 in hepatocellular carcinoma, [23] [24] [25] and in the damaged liver. 26, 27 The close interdependence between ECs, their growth factors, and the liver suggests that liver organogenesis may be dependent on angiogenic events. 28 Similar requirements for ECs have been shown during development of the pancreas, heart, and kidney. 29 After injury, it now also appears that the interaction between ECs and liver regeneration is critical, 30 such that after hepatectomy, inhibition of angiogenic events decreases the rate of hepatic regeneration, and exposure to angiogenic stimuli accelerates hepatic regeneration. New evidence suggests the mechanism in which these angiogenic growth factors protect the liver is through EC-stimulated communication with neighboring parenchymal cells that then induces production of other growth and survival factors, which in turn protects the liver. 31 Regardless of whether the effect is direct or indirect, it appears that the liver vasculature and the growth factors involved in its vascular development are closely interconnected with liver growth itself.
To examine more closely the role of Ang-1 in the development of the liver vasculature, we conditionally expressed Ang-1 in a hepatocyte-specific manner using a tetracycline-based binary conditional transgenic mouse system. Double-transgenic (DT) mice survived gestation but displayed a gross dilation of vessels on the subcapsular surface of the liver. Closer examination revealed loss of portal veins and signs of AV shunt formation, reminiscent of that observed in human liver disease. DT mice with the transgene turned off until adulthood, and then turned on for up to 14 weeks, showed only mild enlargement of surface vessels, suggesting the vascular effects elicited by Ang-1 occurred during development, and that the levels of excess Ang-1 produced in adults was not sufficient to elicit the same phenotype. Interestingly, the developmentally induced vascular phenotype in adults could be completely reversed as early as 2 weeks after turning the transgene off, providing important insight into the importance of angiogenesis in preventing regeneration of the portal venous bed and may explain the continued presence and mechanism of portal hypertension in individuals suffering from liver disease, even in the absence of fibrosis. Our findings may provide novel insight for providing treatment strategies, incorporating not only the targeting of fibrosis but also targeting the liver vasculature and uncontrolled angiogenic events.
Materials and Methods

Transgene Expression Analyses of Transgenic Mice
The pTET-Ang-1 IRES LacZ responder and the liverenriched activator protein (LAP) driver lines have been described previously. [32] [33] [34] Crosses were performed between pTET-Ang-1-IRES LacZ and the LAP tTA lines and offspring were genotyped by polymerase chain reaction (PCR) using DNA extracted from either tail or ear biopsies. DNA was prepared and PCR performed using primers as previously described. 35 Littermates that inherited one or no transgenes served as experimental controls.
Transgene expression was determined using LacZ staining as previously described, 18 reverse transcriptase (RT)-PCR analyses, and Western analyses (see below). Liver RNA was isolated using Trizol (Invitrogen, Carlsbad, CA), DNase treated (Sigma-Aldrich, St. Louis, MO), and a two-step RT-PCR was done (CloneTech, Palo Alto, CA) all according to each manufacturer's suggested protocol. Samples were run in duplicate with one set undergoing RT and a second set containing no RT to control for possible DNA contamination. PCR was completed on cDNA using primers against ␤-actin, mouse Ang-1, and human (transgene-specific) Ang-1 using the following primers: 3Ј␤-actin-CTCTTTGATGTCACGCACGATTTC; 5Ј␤-actin-primer-GTGGGCCGCTCTAGGCACCAA; 3Јhuman Ang-1-primer-TGGGAAGGGAACGAGCCTATT; 5Јhuman Ang-1-primer-AATCATCATAGTTGTGGAACGTAA;3Ј mouse Ang-1-primer-GGGCCGGATCATCATGGTG-GTGG; 5Ј mouse Ang-1-primer-GCCTGGATTTCCA-GAGGGGCTGG.
Western Analysis
Frozen pieces of liver tissue were homogenized in RIPA buffer and quantified using the BCA protein assay (Pierce, Rockford, IL). Equal loading of samples was confirmed by performing Western blotting on 30 g of total protein from liver lysates as described previously, 36 using a monoclonal antibody against ␤-actin (clone AC-15, Sigma) at a 1:5000 dilution. Densitometry was performed when necessary using a GS-800 densitometer (Bio-Rad, Hercules, CA) and Quantity One Software (BioRad). Transgenic hAng-1 protein levels were determined by immunoprecipitating 1 to 2 mg of protein or 300 l of Ang-1-Myc-His-conditioned media (as positive control; as described in Jones and colleagues 37 ) with 1 g of monoclonal anti-His antibody (R&D Systems, Minneapolis, MN) as described previously. 38 Immunoprecipitations were followed by Western blotting with anti-His primary antibody at a 1:500 dilution and a goat anti-mouse horseradish peroxidase-conjugated secondary antibody (1:5000, Stressgen, Victoria, BC, Canada). Blots were stripped and reprobed with a goat polyclonal anti-Ang-1 antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) and a donkey anti-goat secondary (1:5000, Santa Cruz Biotechnology). Blots were reproduced at least three times.
Animal Paradigms
All animals received humane care according to the Canadian Council of Animal Care. Animals were kept on a standard light cycle and fed food and water ad libitum throughout the course of the experiments.
Animals Exposed to Transgenic Ang-1 During Development
Animals were sacrificed by cervical dislocation and the liver removed at 0 weeks (0 days old), 2 weeks (14 days old), between 4 and 12 weeks, and between 36 to 52 weeks of age (Table 1) . To repress pTET Ang-1 IRES LacZ expression in adult mice exposed to the transgene during development, mice were given 100 g/ml doxycycline (Dox) (Sigma) with 5% sucrose in their drinking water. Animals receiving Dox began the regime at 5 or 12 weeks of age, time points in which the liver phenotype was strongly visible (Table 1) . Fresh Dox and sugarsupplemented water was provided at least two times per week for 2, 8, or 12 weeks (Table 1) .
Animals Exposed to Transgenic Ang-1 as Adults
Repression of Ang-1 transgene expression during development was achieved in a similar manner, such that Dox was administered to single transgenic (ST) mothers bred with ST males from the day of the first sign of the vaginal plug. The Dox treatment was maintained from conception until early adulthood, and was removed at the age of 6 weeks. Animals were then sacrificed at 0 days, 4 weeks, between 8 and 9 weeks, and between 12 and 14 weeks after Dox withdrawal.
Perfusion of Mice and Microcomputerized Axial Tomography (CT) Imaging
Control and wild-type littermates (n ϭ 4 control; n ϭ 4 DT), 8 to 12 weeks, were provided with deep anesthesia after an intraperitoneal injection of 6.5 mg/kg sodium pentobarbital. Littermates were perfused transcardially with phosphate-buffered saline containing heparin, followed by 4% paraformaldehyde, and then a solution containing either Microfil MV-122 (livers in Figure 2 ; Flow Tech Inc, Carver, MA) or 5% gelatin and 30 to 40% barium (livers in Figure 3 ), until the vasculature appeared to be filled. Animals were packed in wet ice for 15 minutes to allow for the hardening of gelatin, and the liver was removed and postfixed in 4% paraformaldehyde until processing for micro-CT analyses.
Three-dimensional CT data sets were acquired for each excised liver specimen at 35-m isotropic resolution using an MS-8 micro-CT scanner (EVS Corp., London, Ontario, Canada). With the X-ray source at 80 kVp (mean energy of incident beam, 32 keV), these were acquired in 2.5 hours with 900 views and reconstructed using the Feldkamp algorithm 39 for cone beam CT geometry. Renderings were produced by first segmenting the vessels from the surrounding tissue using seeded region growing, 40 then extracting the vessel surface using marching cubes.
Morphological and Histological Analysis
Whole livers were dissected from the body cavity and immediately photographed with a digital camera. The livers were then dissected into lobes and either fixed overnight in Histochoice tissue fixative (Amresco, Solon, OH) or in 10% buffered formalin alone or in combination with a 1% solution of glutaraldehyde. Additional pieces of R.W.) as described previously. 8 The number in parentheses represents the percentage (%). Wks, weeks of age or treatment.
liver were frozen at Ϫ80°C. Blocks of fixed liver tissue were either embedded in paraffin, cut in 4-m sections using a microtome, and stained with hematoxylin and eosin and Masson's trichrome, or cryopreserved with 30% sucrose, cut in 10-m pieces using a cryostat and subsequently used for immunohistochemistry.
Immunohistochemistry was performed using a goat polyclonal anti-Ang-2 antibody (1:150, Santa Cruz) on formalin-fixed tissue. Conditioned medium from a rat antiTek hybridoma (TEK4; a kind gift from Toshio Suda, Keio University 41 ) was used undiluted at 50 l per section, on Histochoice-fixed tissue. Antigens were detected through the use of a rabbit anti-goat secondary for Ang-2 and a goat anti-rabbit secondary for Tek (both 1:150, Vector Laboratories, Burlingame, CA), an avidin-biotin complex (Vectastain Elite ABC kit; Vector Laboratories), and a diaminobenzidine peroxidase substrate (Vector Laboratories). Slides were counterstained with methyl green (DAKO, Caspinteria, CA), dehydrated in acetone followed by successive xylene immersions, and mounted with Entellan (EM Science). Grading of liver phenotypes was completed by one gastroenterology pathologist specializing in liver pathology (I.R.W.) as described previously. 2 
Results
To gain insight into the role of the angiogenic growth factor Ang-1 in the development of liver vasculature, we expressed Ang-1 in a hepatocyte-specific manner from the onset of liver bud formation, using a Dox-based binary transgenic expression system (Figure 1a) . 32 ,35 DT mice survived gestation at the estimated Mendelian ratio Figure 1 . Generation and characterization of liver-specific Ang-overexpressing mice. a: Two independent lines of mice were used to induce the conditional expression of Ang-1 IRES LacZ. The tetracycline-responsive transactivator (tTA), expressed from the LAP promoter (driver transgene) associates with the tTA-binding site (Tet OS ) upstream of the human Ang-1 cDNA (responder transgene), which was bi-cis-tronically linked to the E. coli LacZ gene via an internal ribosomal entry site (IRES). In the absence of a tetracycline analog (Ϫdrug), Ang-1 is expressed and in the presence of this drug (ϩdrug) Ang-1 expression in suppressed. b: RT-PCR expression analyses demonstrate the presence of human Ang-1 in the absence of Dox and that endogenous mouse Ang-1 levels do not dramatically change; ϩ/Ϫ RT, presence or absence of reverse transcriptase, MMLV. c: Whole cell lysates were blotted with an antibody recognizing mouse Ang-1 and not human Ang-1, confirming that endogenous mouse Ang-1 protein levels do not change in the presence of the transgenic Ang-1. e and g: X-Gal staining in pieces and sections of double-transgenic (DT) adult liver showed strong expression of LacZ. d and f: No staining was observed in the single-transgenic (ST, d) or wild-type (WT, not shown) livers. LacZ expression in all DT mice was confined to the liver because no LacZ staining was observed in the heart (h), kidney (i), spleen (j), lung (k), intestine (l), or skin (m) of the ear. Scale bars: 100 m (l); 50 m (m).
and were similar in size and weight to their littermate controls. RT-PCR analyses for both human Ang-1 and mouse Ang-1 confirmed the expression of transgenicderived human Ang-1 in DT and not in ST littermates (Figure 1b) , and suggested that endogenous Ang-1 levels was not altered between DT and ST mice. No effects on endogenous levels of Ang-1 were confirmed at the protein level using an antibody that recognized mouse Ang-1 but not human Ang-1 ( Figure 1; c and d) . Cell-type specificity of transgenic Ang-1 was confined to hepatocytes in the liver beginning at embryonic day 9.5 ( Figure  1g ) and continued into adulthood, as evidenced by LacZ staining in DT mice and not in ST littermate controls (Figure 1; d to g ). LacZ staining was confined in the DT mouse to the liver, as no staining was observed in the heart, kidney, spleen, lung, intestine, or skin (Figure 1 ; h to m). This expression was extinguished after exposure to Dox in the drinking water (see below).
A range of phenotype in the DT livers was observed with some DT livers having mild alterations in the capsular vasculature although still recognizable as transgenic; whereas others had grossly looking abnormal changes (Figure 2, a and b) . This range in phenotype corresponded to levels of transgenic Ang-1 produced by each mouse (Figure 2 ; a to c). DT mice with severe phenotypes displayed increases in LacZ staining, in addition to increased levels of transgenic Ang-1. There was a remarkable correlation of Ang-1 transgene expression and the severity of the liver phenotype.
At the gross morphological level, DT mice showed a striking dilation of veins on the capsular surface of the liver when compared to control littermates (Figure 3, a  and b) , and micro-CT images of DT mice provided threedimensional evidence for the irregularity of the distribution of the vessels, the marked reduction or pruning of the portal venous tree, and confirmed the gross observations of hepatic vein dilatation on the liver surface (Figure 2a and Figure 3 , c to f). Histological examination of control mice and DT mice provided further verification of these macro-observations, such that control mice had normal livers containing large regular portal veins extending to the subcapsular region (Figure 3g ) whereas the DT mice had notably dilated and irregularly shaped portal veins (Figure 3h ). In addition to the venous dilation, a distinct reduction of portal vein branches was observed ( Figure  3 ; c to h) and was accompanied by numerous irregular arterial branches unaccompanied by portal veins (see below).
Control mice had normal livers in which the portal veins were large and regular and no unaccompanied arteries were ever witnessed in these livers (Figure 4, a and b) . Closer examination of control and DT livers revealed a significant reduction of portal vein branches in the DT livers (Figure 2a (Figure 4c ). In addition, the reduction in portal vein branches was often accompanied by numerous irregular arterial branches ( Figure 4 , e and f). These arterial sprouts closely approached the hepatic veins suggesting the possibility of AV shunts. These phenotypic changes were quantitatively and qualitatively similar at all ages sampled beginning as early as 4 weeks of age and extending up to 52 weeks (Table 1) .
In vessels undergoing angiogenesis, Tie2 and Ang-2 protein levels were increased in ECs ( Figure 5 ). Tie2 in ST, WT, and DT livers was seen in the ECs of hepatic veins and portal veins and arteries ( Figure 5 ; a and b, e and f) and of particular interest was the observation of Tie2 immunoreactivity in the putative AV sprouts in the DT livers ( Figure 5, e and f) . In WT and ST mice, liver ECs showed very little or no basal expression of Ang-2 ( Figure  5, c and d) , whereas DT liver ECs showed increases in Ang-2 staining in remodeled hepatic veins and some sinusoidal endothelium ( Figure 5, g and h) . Both Tie2 and Ang-2 expression was increased in remodeled ECs, consistent with the suggested role of Ang-2. 42 This role suggests that Ang-2 acts as a Tie2 antagonist leading to the destabilization of quiescent blood vessels, such that in the absence of concurrent expression of vascular endothelial growth factor, the ECs will die via apoptosis, whereas when expressed in the presence of vascular endothelial growth factor, the ECs will undergo mitosis, with the end result in both cases being vascular remodeling. 43 To determine the age of onset of these phenotypic changes, we examined livers taken from postnatal day 0 and postnatal day 15 (2 weeks old) mice (Table 1) . No differences in sinusoidal size were found in 0-day-old DT mice but at 2 weeks of age, sinusoidal dilation began appearing in the presence of normal peripheral portal veins. By 4 weeks of age, visible arterial sprouting was observed along with dilatation of hepatic veins and a marked reduction in portal veins (Table 1) . No evidence of thrombosis or other degenerative changes was seen in these animals.
A minority of DT mice had more extreme vascular changes, including hepatic vein remodeling (Figure 6a ) and focal necrosis (Figure 6b , Table 1 ). Moreover, large hepatocellular nodules ( Figure 6 ; c to e) were observed in two of three animals between 36 to 52 weeks of age, representing either a hyperplastic or a neoplastic phenomenon, and these regions were often marked with significant dilatation of sinusoids also referred to as peliosis hepatis (Figure 6f) .
To determine whether the liver phenotype required the continued expression of Ang-1, groups of animals were given Dox to suppress Ang-1 expression for 2, 8, or 12 weeks beginning either at 5 weeks or 12 weeks of age ( Table 1 ). The suppression of the transgenic Ang-1 was confirmed at the protein level (Figure 7a Table 1) suggesting that reversal of the Ang-1-mediated phenotype could be resolved as quickly as 2 weeks. Because the portal veins were present in standard arrangement, the branching of portal tracts out to the periphery appeared to be normal and no irregular sprouts were seen except in the one animal ( Figure 7, b to d) . This silencing of Ang-1 expression was accompanied by a noticeable restoration toward wild-type morphology including a de- crease in arterial sprouting and a remarkable development of the peripheral portal venous tree such that customary portal tracts were identified in a near classic arrangement in the peripheral tissue. Animals left untreated had severe phenotypic abnormalities. In mice treated with Dox for 2 weeks, we noted partial regression of the hepatocellular phenotype such that a micronodular pattern (Figure 7e ) appeared in which the healthier hepatocytes appeared to develop in the regions of the hepatic veins.
To assess whether the liver phenotype formed as a result of excess Ang-1 during development, or whether we could recapitulate the phenotype by expressing Ang-1 in adulthood only, groups of animals were given Dox to suppress Ang-1 expression beginning at the time of conception until 6 weeks of age. Dox was removed and animals were evaluated 0 days (Figure 8, a and (a and b) , and very low basal levels of Ang-2 (c and d). e and f: Tie2 levels increase in DT mice undergoing angiogenic remodeling, and are seen in hepatic veins and AV sprouts. g and h: Significant increases in Ang-2 levels are observed in DT mice and appear to occur in vessels undergoing angiogenic remodeling. Scale bar, 50 m.
of LacZ staining and after 4 weeks of Dox withdrawal, DT livers showed small alterations in the capsular surface vasculature at the lateral edges of the liver (Figure 8b) , with low levels of LacZ staining. These findings were confirmed at 8 and 14 weeks after Dox removal (Figure 8;  c and d, g and h) , in which only moderate increases in vessel size were observed. Transgenic Ang-1 expression (indicated by LacZ staining), albeit present, did not ever reach the levels achieved during development (Figure 1 , e and g) suggesting that perhaps if the developmental levels of Ang-1 could be attained the phenotype might be recapitulated in its entirety.
Discussion
Here, we conditionally expressed Ang-1 in a hepatocytespecific manner to determine the role of Ang-1 in liver development. DT mice lived through gestation but displayed a gross dilation of vessels on the subcapsular surface of the liver. Closer examination revealed a loss of portal veins and signs of AV shunt formation similar to that observed in human liver disease. In more severe cases, focal growths, peliosis, areas of focal necrosis, and hepatic vein remodeling were found. Most interesting was the finding that these phenotypes were completely reversed 2 weeks after extinguishing transgene expression, and may occur via a mechanism of nodular regeneration. In contrast to these developmental results, we were unable to recapitulate the phenotype in mice exposed to excess Ang-1 beginning in adulthood. This may simply reflect the lower transgenic Ang-1 levels we obtained after 9 weeks of transgene suppression.
In mice exposed to Ang-1 throughout development, we observed dilation of hepatic veins, loss of portal veins, and the formation of AV shunts (evidenced by Tie2-pos- itive immunoreactivity) in the Ang-1-expressing mice. The presence of dilated hepatic veins and portal vein hypoplasia may reflect either the loss of directionality because of expression of the Ang-1 in hepatocytes or perhaps the high ambient blood pressure in the sinusoidal bed leading to lack of development of the portal veins. This latter theory is supported by our developmental observations that no differences in sinusoidal size were observed in the 0-day-old DT mice and that by 2 weeks of age sinusoidal dilation begins appearing in the presence of normal peripheral portal veins, however by 4 weeks of age, visible arterial sprouting accompanied by dilatation of hepatic veins and a marked reduction in portal veins was seen. These shunts appear to be a result of Ang-1-induced sprouting angiogenesis confirming reports of others that showed Ang-1-mediated sprouting in vitro 44 -46 and in vivo. 47 These findings suggest that the dilatation of hepatic veins and sinusoids appears to be secondary to increased arterial flow. Consistent with this interpretation is that during this period of postnatal development, the liver is maturing with rapid elongation of the portal tracts (including the portal arteries) therefore the portal vein hypoplasia observed most likely represents the failure of these veins to develop. This theory is further supported in that no evidence of thrombosis or other degenerative changes were observed in these animals. Additional evidence supporting this theory is that in adult DT mice in which transgene expression was suppressed until development and maturation had occurred, no portal vein hypoplasia was observed, rather mild to moderate vascular dilation, confirming previous reports of increased vascularization and vessel diameter after exposure to Ang-1 in the skin and heart. 34, 47, 48 Notwithstanding these arguments, as the Ang-1 transgene levels were significantly less than Ang-1 levels obtained during development, we cannot rule out a dose-response effect, such that if the Ang-1 protein levels were higher in the adult, sprouting could occur, leading to portal vein stasis, thrombosis, and hepatic vein dilation.
In the more severely affected DT mice exposed to Ang-1 during development, focal necrosis, large hepatocellular nodules, venous remodeling, and peliosis hepatis were all observed. Unique to this model is its similarity to the human condition of FNH which is accompanied with longstanding augmentation of angiogenesis, and recently has been found to correlate with increased Ang-1 expression. 27 It has been demonstrated that some FNH lesions are associated with hepatic vein obstruction, and this event may trigger a secondary hormonal response that augments the regenerative capacity of the hepatocytes in the affected regions. 49 -51 Both animals with the large nodules had evidence of previous obliteration of medium and large hepatic veins in the region of the tumors, suggesting that this may be an early lesion rather than a secondary event.
To assess whether the observed developmental phenotypes were Ang-1-dependent and could be reversed, we silenced transgene expression by exposing the animals to Dox in their water as reported previously. 35, 41 The finding of normal portal veins and absence of arterial sprouts after only 2 weeks of suppression of Ang-1 is consistent with the view that inhibition of an ongoing chronic angiogenic stimulus may have allowed the veins to grow and, indeed, catch up with the development of other portal tract elements. We interpret this to be a result of a partial reduction in the arterial flow near the portal tracts and nearly complete reduction of pressure in the more peripheral regions near the hepatic veins. Of particular interest in mice treated with Dox for 2 weeks was the noted partial regression of the hepatocellular phenotype. We observed a micronodular pattern in which the healthier hepatocytes appeared to develop in the regions of the hepatic veins, whereas this restitution had not yet occurred in the periportal regions suggesting the return of the hepatocytes to their normal phenotype may be related to the character of the blood flow or pressure in the sinusoids. There is striking similarity of this nodular pattern to conditions in the human liver of NRH 52 and nodularity adjacent to infarcts of Zahn 53 where angiogenesis is known to occur. 54 The finding of large nodules in two of our older DT animals and a pattern of NRH after withdrawal of Ang-1 expression in two animals suggest that this model may be useful for the study of these various nodular lesions of the human liver. However, it must be noted that the severity of the phenotype of these mice was assumed to not include the hepatocellular nodules and focal necrosis phenotypes, as these were observed only in older mice, and we began Dox treatment at 5 weeks of age. Thus our conclusions regarding reversibility should be limited to include reversal of the enlarged arteries, arterial sprouting, dilation of hepatic veins, and portal vein hypoplasia.
Angiogenesis occurs during the development of cirrhosis, NRH, FNH, Budd-Chiari syndrome, hepatitis, and hepatocellular carcinoma. The present model has many features that may aid in the elucidation of possible mechanisms involved in the development and regression of the angiogenic component of human cirrhosis and other chronic hepatic lesions. Human liver diseases are accompanied by marked obliteration of the peripheral portal and hepatic veins with secondary sprouting of the arterioles. 1, 4, 8, 17 In fact, in human cirrhosis the fibrous septa may disappear throughout time while the disease is inactive nonetheless, the portal hypertension often remains, along with histological evidence of unaccompanied arteries in the parenchyma as seen in this animal model. This situation suggests that the limiting step in the regression of cirrhosis is not removal of collagen but rather the regeneration of the portal venous circuit. It offers the possibility that the secondary angiogenesis may be preventing the restitution of the portal vein circuit and offers the hope that the control of excessive angiogenesis in the cirrhotic liver may aid the regression of cirrhosis and portal hypertension.
Our developmental model provides a liver phenotype reminiscent of the human diseases, whereas our adult onset has yet to be able to reproduce the same effects. This work, albeit not an exact animal model of liver disease, does provide important insight into the importance of angiogenesis in preventing regeneration of the portal venous bed and may explain the continued presence and mechanism of portal hypertension in individuals with otherwise regressed cirrhosis. Our findings may provide additional information that may aid in providing treatment strategies, incorporating the targeting of fibrotic events or hepatocyte toxicity, in addition to targeting the liver vasculature and uncontrolled angiogenesis.
